Trial Profile
A Phase II Study of AT-101 in Recurrent Extensive Stage Small Cell Lung Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs AT 101 (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 21 Nov 2012 Actual end date changed from Aug 2010 to Oct 2009 as reported by ClinicalTrials.gov.
- 21 Nov 2012 Actual end date changed from Aug 2010 to Oct 2009 as reported by ClinicalTrials.gov.
- 18 Jun 2012 Actual end date changed from Aug 2010 to Oct 2009 as reported by ClinicalTrials.gov.